The startup provides contract development and manufacturing services for lentiviral vectors, utilizing customized design and cloning tools tailored to client specifications. This enables researchers to conduct targeted tests on rare diseases and hematological cancers, facilitating advancements in gene therapy and personalized medicine.
Funding
$11.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of gene therapies and personalized medicine requires specialized manufacturing of lentiviral vectors, which can be challenging and resource-intensive for research organizations, especially when targeting rare diseases or hematological cancers. Meeting stringent regulatory requirements, such as those from the EMA and FDA, further complicates in-house lentiviral vector production.
Solution
VIVEbiotech is a contract development and manufacturing organization (CDMO) specializing in GMP-grade lentiviral vector production. The company offers end-to-end services, from customized design and cloning to large-scale manufacturing, to meet the specific requirements of each lentiviral vector. VIVEbiotech leverages its expertise in virology and process optimization to provide scalable, cost-effective, and regulatory-compliant lentiviral vectors. Their platform is designed to facilitate both ex-vivo and in-vivo administration for treating hematological and solid cancers, as well as rare diseases.
Target Audience
VIVEbiotech serves biotech and pharmaceutical companies, as well as research institutions, that are developing gene therapies and require lentiviral vector manufacturing services.
Features
- GMP-grade lentiviral vector development and manufacturing
- Exclusive specialization in lentiviral vectors
- Customized design and cloning services tailored to client specifications
- Process optimization for both Upstream (USP) and Downstream (DSP) production
- Manufacturing platform suitable for both Developmental Engineering and GMP batches
- Compliance with EMA and FDA regulatory requirements
- Seven clean rooms dedicated exclusively to lentivirus production